🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

120 results for “Ningbo” Clear

  1. -

    Ningbo Cancer Hospital

    Unresectable intrahepatic cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  2. A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  3. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  4. BAY 1841788, DEGARELIX , LEUPRORELIN , TRIPTORELIN , GOSERELIN , TRIPTORELIN PAMOATE

    Ningbo Cancer Hospital

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  5. CALCIUM FOLINATE, ivonescimab, CALCIUM LEVOFOLINATE, OXALIPLATIN, FLUOROURACIL

    Ningbo Cancer Hospital

    Advanced biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  6. CAPECITABINE, CAPECITABINE, NUBEQA 300 mg film-coated tablets

    Ningbo Cancer Hospital

    Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.

    phase 2 small molecule active

    1 trial

  7. CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.

    phase 2 small molecule active

    1 trial

  8. CAPECITABINE, Lonsurf 15 mg/6.14 mg film-coated tablets, FOLINIC ACID, FLUOROURACIL, OXALIPLATIN, NIVOLUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, LEVOLEUCOVORIN

    Ningbo Cancer Hospital

    Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  10. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  11. Calquence 100 mg film-coated tablets, ACALABRUTINIB

    Ningbo Cancer Hospital

    Disseminated large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  12. Capecitabine Accord 500 mg film-coated tablets

    Ningbo Cancer Hospital

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  13. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etomedac 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung

    Ningbo Cancer Hospital

    Stage IIA/B seminoma

    phase 2 small molecule active

    1 trial

  14. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herst

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial

  15. Cotellic 20 mg film-coated tablets, Ginisortamab

    Ningbo Cancer Hospital

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  17. DS-8201a

    Ningbo Cancer Hospital

    Metastatic Breast Cancer HR+, HER2-

    phase 2 small molecule active

    1 trial

  18. EXEMESTANE, ANASTROZOLE, LETROZOLE

    Ningbo Cancer Hospital

    Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

    phase 2 small molecule active

    1 trial

  19. EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN

    Ningbo Cancer Hospital

    Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.

    phase 2 small molecule active

    1 trial

  20. Etoposide 20 mg/ml Concentrate for solution for infusion , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporządzania roztworu do wstrzykiwań / do infuzji

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  21. Faslodex 250 mg solution for injection., PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  22. HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  23. IBRANCE 75 mg hard capsules, EXEMESTANE, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, TAMOXIFEN, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, IBRANCE 125 mg hard capsules, ANASTROZOLE, IBRANCE 75 mg hard capsules, CYCLOPHOSPHAMIDE, DOCETAXEL, IBRANCE 100 mg hard capsules, IBRANCE 100 mg film-coated tablets, IBRANCE 100 mg hard capsul

    Ningbo Cancer Hospital

    Localized ER+ breast cancer

    phase 2 small molecule active

    1 trial

  24. IFOSFAMIDE, CISPLATIN, PACLITAXEL, METHYLPREDNISOLONE, RANITIDINE, MESNA, APREPITANT, DEXCHLORPHENIRAMINE MALEATE

    Ningbo Cancer Hospital

    Penis carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources